These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32386481)

  • 1. Kallikrein-related peptidase (KLK10) cessation blunts colorectal cancer cell growth and glucose metabolism by regulating the PI3K/Akt/mTOR pathway.
    Wei H; Dong C; Shen Z
    Neoplasma; 2020 Jul; 67(4):889-897. PubMed ID: 32386481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
    Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
    J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
    Wu K; Wu B; Yan K; Ding Q; Miao Z
    Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling.
    Wang K; Huang W; Sang X; Wu X; Shan Q; Tang D; Xu X; Cao G
    Phytomedicine; 2020 Mar; 68():153191. PubMed ID: 32135457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H4 facilitates proliferation and metastasis of colorectal carcinoma cell through PI3K/Akt/mTOR signaling pathway.
    Li C; Zhan Y; Ma X; Fang H; Gai X
    Clin Exp Med; 2020 Feb; 20(1):79-86. PubMed ID: 31664539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of FOXO6 inhibits the proliferation, invasion, and glycolysis in colorectal cancer cells.
    Li Q; Tang H; Hu F; Qin C
    J Cell Biochem; 2019 Mar; 120(3):3853-3860. PubMed ID: 30321450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway.
    Zhang JJ; Xu WR; Chen B; Wang YY; Yang N; Wang LJ; Zhang YL
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8321-8331. PubMed ID: 31646562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukotriene B4 receptor knockdown affects PI3K/AKT/mTOR signaling and apoptotic responses in colorectal cancer.
    Tang C; Wang A; Zhao Y; Mou W; Jiang J; Kuang J; Sun B; Tang E
    Biomol Biomed; 2024 Jan; 24(4):968-981. PubMed ID: 38259082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
    Moench R; Grimmig T; Kannen V; Tripathi S; Faber M; Moll EM; Chandraker A; Lissner R; Germer CT; Waaga-Gasser AM; Gasser M
    Oncotarget; 2016 Oct; 7(42):68749-68767. PubMed ID: 27626684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressive effect of scavenger receptor class A member 5 overexpression in colorectal cancer by regulating PI3K/AKT/mTOR pathway.
    Li Y; Peng F; Tan X; Wang J; Xu Y
    Genes Genomics; 2021 Oct; 43(10):1189-1198. PubMed ID: 34417976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deoxyshikonin isolated from
    Zhu Y; Zhong Y; Long X; Zhu Z; Zhou Y; Ye H; Zeng X; Zheng X
    Pharm Biol; 2019 Dec; 57(1):412-423. PubMed ID: 31230505
    [No Abstract]   [Full Text] [Related]  

  • 12. SPAG4 enhances mitochondrial respiration and aerobic glycolysis in colorectal cancer cells by activating the PI3K/Akt signaling pathway.
    Zhou J; Sun H; Zhou H; Liu Y
    J Biochem Mol Toxicol; 2024 Nov; 38(11):e70009. PubMed ID: 39410830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of GRHL2 inhibited proliferation and induced apoptosis of colorectal cancer by suppressing the PI3K/Akt pathway.
    Hu F; He Z; Sun C; Rong D
    Gene; 2019 Jun; 700():96-104. PubMed ID: 30917932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NES1/KLK10 promotes trastuzumab resistance via activation of PI3K/AKT signaling pathway in gastric cancer.
    Tang L; Long Z; Zhao N; Feng G; Guo X; Yu M
    J Cell Biochem; 2018 Aug; 119(8):6398-6407. PubMed ID: 29231994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
    Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
    Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway.
    Zhong J; Ding S; Zhang X; Di W; Wang X; Zhang H; Chen Y; Zhang Y; Hu Y
    Front Biosci (Landmark Ed); 2023 Feb; 28(2):37. PubMed ID: 36866550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.
    Liu Y; Zhao Y; Guo L
    Mol Cell Endocrinol; 2016 Jan; 420():208-16. PubMed ID: 26549689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways.
    Duan S; Huang W; Liu X; Liu X; Chen N; Xu Q; Hu Y; Song W; Zhou J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):304. PubMed ID: 30518405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.
    Chen GQ; Tang CF; Shi XK; Lin CY; Fatima S; Pan XH; Yang DJ; Zhang G; Lu AP; Lin SH; Bian ZX
    Oncotarget; 2015 Sep; 6(27):24148-62. PubMed ID: 26160839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.